Vizgen Secures $37M Series B Financing To Advance Spatial Genomics Through Commercialization Of Merscope™ Platform
Apr 07, 2021•over 4 years ago
Amount Raised
$37 Million
Round Type
series b
Description
Vizgen, the life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing. The financing was co-led by Novalis LifeSciences LLC, and current investor Northpond Ventures. Also participating in the round were new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech